Jazz Hits A High Note With Luvox Resubmissions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has accepted complete response to “approvable” on Solvay’s Luvox CR, putting U.S. commercialization partner Jazz a step closer to market with the extended-release fluvoxamine formulation.